Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results | Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals reported 2026 fiscal year-end results, highlighting growth in REDEMPLO prescriptions and regulatory approvals in the U.S. and Europe. The company also announced progress in its plozasiran program, including FDA STAR program entry and positive clinical trial results. Additionally, Arrowhead presented promising data for ARO-DIMER-PA and ARO-MAPT, its investigational RNAi therapeutics.
How this was made
The 30-second read
Why it matters
The combination of prescription growth and pivotal trial readouts provides fresh, material information that could shift investor expectations.
Market read
First‑time disclosure of strong commercial uptake and Phase 3 efficacy data is likely to move ARWR and influence the RNAi biotech niche.
What to watch
Potential reimbursement challenges in Europe and the need for FDA STAR program approval could delay commercial rollout.
Background
Arrowhead Pharmaceuticals released its FY2026 year‑end financials and detailed commercial and clinical updates for its lead products.
Ticker impact
Arrowhead Pharmaceuticals reported FY2026 results, highlighting a 63% QoQ growth in new REDEMPLO prescriptions and positive Phase 3 data for plozasiran in severe hypertriglyceridemia.
likely upward pressure as investors price in commercial momentum and regulatory progress
New prescription growth and Phase 3 efficacy data are first‑time disclosures that materially improve the company's near‑term outlook.
Market effects
Positive data for RNAi therapeutics may boost sentiment toward the broader biotech and gene‑silencing sector.
U.S. biotech investors may see a short‑term rally; European markets could react to the UK and Germany authorizations.
The regulatory milestones and trial results have global relevance for lipid‑lowering therapies.
Counterpoint
If the market has already priced in the trial success, the stock could face a sell‑off on profit‑taking.
Key entities
- companyArrowhead Pharmaceuticals
US‑listed biotech developing RNAi therapeutics.
- productREDEMPLO
RNAi therapy for familial chylomicronemia syndrome.
- productplozasiran
RNAi candidate for severe hypertriglyceridemia.
